Literature DB >> 8473677

Influence of natural antigenic exposure on expiratory flows, methacholine responsiveness, and airway inflammation in mild allergic asthma.

L P Boulet1, H Turcotte, M Boutet, L Montminy, M Laviolette.   

Abstract

BACKGROUND: This study looked at respiratory symptoms, peak expiratory flow rates (PEFRs), airway responsiveness to methacholine and inflammatory changes on bronchial biopsies, bronchial lavage (BL), and bronchoalveolar lavage (BAL) during natural antigenic exposure in nine subjects with pollen-sensitized seasonal asthma.
METHODS: The subjects recorded daily symptoms of asthma, cough and rhinitis, and morning and evening PEFRs between January and September, during and out of the pollen exposure. Baseline forced expiratory volume in 1 second, forced vital capacity, and methacholine responsiveness were measured every 3 to 4 weeks. BAL, BL, and bronchial biopsies were performed in the pollen season at the initial increase of asthma symptoms and out of pollen exposure.
RESULTS: At the time of bronchoscopy during the pollen season compared with out of season, asthmatic subjects had an increase in asthma symptom score (1.18 +/- 0.24/0.44 +/- 0.18, p < 0.05), a reduction of PEFR (407 +/- 23/442 +/- 20 L/min, p = 0.02), and a decrease in PC20 (1.15/1.48 mg/ml, p = 0.05). In asthmatic subjects, median BAL and BL cell counts and cell differentials during or out of antigenic exposure were similar, but BAL and BL eosinophils and metachromatic cells counts were always higher than in healthy subjects. In comparison with controls, biopsies obtained in asthmatic subjects showed airway lesions such as epithelial desquamation, squamous cell metaplasia, thickening of basal membrane, inflammatory cells (p < 0.05 for neutrophils), edema, and ciliary abnormalities. During pollen exposure, inflammatory signs increased, but this change was only significant for the extent of epithelial desquamation and neutrophil counts. No significant correlation was found between the intensity of airway inflammation and changes in airway responsiveness.
CONCLUSIONS: In subjects with mild allergic asthma and pollen-induced asthma, seasonal antigenic exposure was associated with an increase in epithelial shedding and in the number of neutrophils on bronchial biopsies, suggesting a mild increase in baseline airway inflammation. However, these changes were not correlated with increases in airway responsiveness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473677     DOI: 10.1016/0091-6749(93)90346-h

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

Review 1.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

Review 2.  Seasonal variation in bronchial hyperreactivity (BHR) in allergic patients.

Authors:  S A Tilles; E J Bardana
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

Review 3.  Climate change. A global threat to cardiopulmonary health.

Authors:  Mary B Rice; George D Thurston; John R Balmes; Kent E Pinkerton
Journal:  Am J Respir Crit Care Med       Date:  2014-03-01       Impact factor: 21.405

4.  Enhancement of Antigen-specific functional responses by neutrophils from allergic patients.

Authors:  J Monteseirín; M J Camacho; R Montaño; E Llamas; M Conde; M Carballo; P Guardia; J Conde; F Sobrino
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

5.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigen-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; D A Burroughs; M Yeadon; C P Page
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

Review 6.  Neutrophils in asthma pathophysiology.

Authors:  Madeleine Ennis
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.